Cancer Chemotherapy and Pharmacology

, Volume 64, Issue 1, pp 27–33

A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma

Authors

  • Sun Jin Sym
    • Department of Internal MedicineAsan Medical Center, University of Ulsan College of Medicine
    • Department of Internal MedicineGachon University Gil Hospital
  • Dae Ho Lee
    • Department of Internal MedicineAsan Medical Center, University of Ulsan College of Medicine
  • Hye Jin Kang
    • Department of MedicineKorea Institute of Radiological and Medical Sciences
  • Seung Hyun Nam
    • Department of Internal MedicineSeoul Veterans Hospital
  • Ho Young Kim
    • Department of Internal Medicine, Sacred Heart HospitalCollege of Medicine, Hallym University
  • Seok Jin Kim
    • Department of Internal MedicineCollege of Medicine, Korea University
  • Hyeon Seok Eom
    • Hematology–Oncology Clinic, Research Institute and HospitalNational Cancer Center
  • Won Seog Kim
    • Department of Medicine, Samsung Medical CenterSchool of Medicine, Sungkyunkwan University
    • Department of Internal MedicineAsan Medical Center, University of Ulsan College of Medicine
Original Article

DOI: 10.1007/s00280-008-0847-y

Cite this article as:
Sym, S.J., Lee, D.H., Kang, H.J. et al. Cancer Chemother Pharmacol (2009) 64: 27. doi:10.1007/s00280-008-0847-y

Abstract

Purpose

We investigated the efficacy and toxicity of the etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx), in which oxaliplatin (Ox) was substituted for cisplatin in the ESHAP [etoposide (E), methylprednisolone (S), high-dose cytarabine (HA), and cisplatin (P)] regimen, for patients with refractory/relapsed aggressive non-Hodgkin’s lymphoma (NHL).

Materials and methods

The ESHAOx consisted of E (40 mg/m2 on days 1–4), S (500 mg on days 1–5), HA (2 g/m2 on day 5), and Ox (130 mg/m2 on day 1) every 3 weeks to a maximum of six cycles. Responses were assessed every three cycles.

Results

Twenty-seven patients were enrolled (19 with relapsed and 8 with refractory; 10 with an IPI score of 3–5). The overall response rate was 63% [95% confidence interval (95% CI) 45–81%], including eight complete remissions (CR) and one unconfirmed CR (33%). The median duration of response was 9.9 months (95% CI 5.7–14.2 months). After a median follow-up of 18.6 months, the median progression-free and overall survival was 5.3 months (95% CI 3.9–6.7 months) and 15.1 months (95% CI 9.4–20.9 months), respectively, with a 1-year survival rate of 61.5%. Most common grade 3/4 hematologic toxicities were neutropenia (56%) and thrombocytopenia (35%), whereas no patient experienced grade 3/4 renal or neurotoxicity.

Conclusion

The efficacy and toxicity profiles suggested that the ESHAOx can be an alternative option for patients with refractory/relapsed aggressive NHL.

Keywords

OxaliplatinLymphomaSalvage therapyChemotherapy

Copyright information

© Springer-Verlag 2008